Table 2.
Baseline Rheumatic Disease Characteristics of Systemic Autoimmune Rheumatic Disease (SARD) Patients with COVID-19
| Characteristics* | SARD Patients (n = 2,379) |
|---|---|
| Rheumatic Disease, n (%)** | |
| Rheumatoid Arthritis | 1,181 (50) |
| Systemic Lupus Erythematosus | 528 (22) |
| Sjögren’s Syndrome | 317 (13) |
| Systemic Sclerosis | 92 (4) |
| Dermatomyositis/PM | 79 (3) |
| Other CTD† | 188 (8) |
| Systemic Vasculitis | 175 (7) |
| Psoriatic Arthritis | 200 (8) |
| Ankylosing Spondylitis | 76 (3) |
| Rheumatic Disease Medications, n (%) | |
| Glucocorticoids | 1,304 (55) |
| Conventional DMARDs‡ | 981 (41) |
| Azathioprine | 80 (3) |
| Cyclophosphamide | 20 (1) |
| Cyclosporine | 58 (2) |
| Hydroxychloroquine | 534 (22) |
| Leflunomide | 45 (2) |
| Methotrexate | 302 (13) |
| Mycophenolate/mycophenolic acid | 160 (7) |
| Sulfasalazine | 55 (2) |
| Tacrolimus | 92 (4) |
| Biologic/targeted synthetic DMARDs§ | 374 (16) |
| B-cell activating factor inhibitor | 17 (1) |
| CD20 inhibitor | 60 (3) |
| CTLA-4 immunoglobulin | 38 (2) |
| IL-1 inhibitor | <10 (<1) |
| IL-6 receptor inhibitor | 38 (2) |
| IL-17 inhibitor | 26 (1) |
| IL-23 inhibitor | 23 (1) |
| JAK inhibitor | 56 (2) |
| TNF inhibitor | 200 (8) |
Assessed in year prior to index date. SARD, systemic autoimmune rheumatic disease; PM, polymyositis; CTD, connective tissue disease; TNF, tumor necrosis factor; DMARD, disease-modifying anti-rheumatic drug; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; IL, interleukin; JAK, janus kinase.
Some patients may have more than one rheumatic disease diagnosis.
Other CTD includes mixed connective tissue disease and undifferentiated connective tissue disease.
Includes azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate/mycophenolic acid, sulfasalazine, tacrolimus.
Includes B-cell activating factor inhibitors (belimumab), CD20 inhibitors (rituximab, ocrelizumab, ofatumumab), CTLA-4 immunoglobulin (abatacept), IL-1 inhibitors (anakinra, canakinumab, rilonacept), IL-6 receptor inhibitors (tocilizumab, sarilumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), IL-23 inhibitors (ustekinumab, guselkumab, risankizumab, tildrakizumab), JAK inhibitors (upadacitinib, baricitinib, tofacitinib), TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab).